Literature DB >> 29552127

Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells.

Fernando Francisco Borges Resende1, Simoneide Souza Titze-de-Almeida1, Ricardo Titze-de-Almeida1.   

Abstract

Astrocytic tumors, including astrocytomas and glioblastomas, are the most common type of primary brain tumors. Treatment for glioblastomas includes radiotherapy, chemotherapy with temozolomide (TMZ) and surgical ablation. Despite certain therapeutic advances, the survival time of patients is no longer than 12-14 months. Cancer cells overexpress the neuronal isoform of nitric oxide synthase (nNOS). In the present study, it was examined whether the nNOS enzyme serves a role in the damage of astrocytoma (U251MG and U138MG) and glioblastoma (U87MG) cells caused by TMZ. First, TMZ (250 µM) triggered an increase in oxidative stress at 2, 48 and 72 h in the U87MG, U251MG and U138MG cell lines, as revealed by 2',7'-dichlorofluorescin-diacetate assay. The drug also reduced cell viability, as measured by MTT assay. U87MG cells presented a more linear decline in cell viability at time-points 2, 48 and 72 h, compared with the U251MG and U138MG cell lines. The peak of oxidative stress occurred at 48 h. To examine the role of NOS enzymes in the cell damage caused by TMZ, N(ω)-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole (7-NI) were used. L-NAME increased the cell damage caused by TMZ while reducing the oxidative stress at 48 h. The preferential nNOS inhibitor 7-NI also improved the TMZ effects. It caused a 12.8% decrease in the viability of TMZ-injured cells. Indeed, 7-NI was more effective than L-NAME in restraining the increase in oxidative stress triggered by TMZ. Silencing nNOS with a synthetic small interfering (si)RNA (siRNAnNOShum_4400) increased by 20% the effects of 250 µM of TMZ on cell viability (P<0.05). Hoechst 33342 nuclear staining confirmed that nNOS knock-down enhanced TMZ injury. In conclusion, our data reveal that nNOS enzymes serve a role in the damage produced by TMZ on astrocytoma and glioblastoma cells. RNA interference with nNOS merits further studies in animal models to disclose its potential use in brain tumor anticancer therapy.

Entities:  

Keywords:  RNA interference; cancer; glioblastoma; nitric oxide; nitric oxide synthase; oxidative stress

Year:  2018        PMID: 29552127      PMCID: PMC5840643          DOI: 10.3892/ol.2018.7917

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  84 in total

Review 1.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

Review 2.  Central nervous system gliomas.

Authors:  Michele Reni; Elena Mazza; Silvia Zanon; Gemma Gatta; Charles J Vecht
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-22       Impact factor: 6.312

3.  Origin of the U87MG glioma cell line: Good news and bad news.

Authors:  Marie Allen; Mia Bjerke; Hanna Edlund; Sven Nelander; Bengt Westermark
Journal:  Sci Transl Med       Date:  2016-08-31       Impact factor: 17.956

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.

Authors:  Dong-Ping Sang; Ru-Jun Li; Qing Lan
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

Review 6.  Role of nitric oxide in tumour progression: lessons from human tumours.

Authors:  L L Thomsen; D W Miles
Journal:  Cancer Metastasis Rev       Date:  1998-03       Impact factor: 9.264

Review 7.  Nitric oxide, cell signaling and cell death.

Authors:  Gilbert A Blaise; Dominique Gauvin; Marius Gangal; Simon Authier
Journal:  Toxicology       Date:  2005-03-15       Impact factor: 4.221

Review 8.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.

Authors:  Yongzhi Wang; Tao Jiang
Journal:  Cancer Lett       Date:  2013-01-20       Impact factor: 8.679

9.  Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells.

Authors:  Charles S Cobbs; Thomas R Whisenhunt; Duane R Wesemann; Lualhati E Harkins; Erwin G Van Meir; Minu Samanta
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

10.  Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme.

Authors:  Amanda Tivnan; Zaitun Zakaria; Caitrín O'Leary; Donat Kögel; Jenny L Pokorny; Jann N Sarkaria; Jochen H M Prehn
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

View more
  5 in total

1.  Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons.

Authors:  Naomi Lomeli; Kaijun Di; Diana C Pearre; Tzu-Feng Chung; Daniela A Bota
Journal:  Mitochondrion       Date:  2020-02-08       Impact factor: 4.160

2.  Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment.

Authors:  Natalia Oddone; Frank Boury; Emmanuel Garcion; Andreas M Grabrucker; M Carmen Martinez; Federica Da Ros; Anna Janaszewska; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi; Barbara Ruozi; Jason T Duskey
Journal:  Front Pharmacol       Date:  2020-05-04       Impact factor: 5.810

3.  Current promising treatment strategy for glioblastoma multiform: A review.

Authors:  Sanjib Bahadur; Arvind Kumar Sahu; Pragya Baghel; Suman Saha
Journal:  Oncol Rev       Date:  2019-07-25

4.  Delivery of miRNA-Targeted Oligonucleotides in the Rat Striatum by Magnetofection with Neuromag®.

Authors:  Simoneide Souza Titze de Almeida; Camila Hillesheim Horst; Cristina Soto-Sánchez; Eduardo Fernandez; Ricardo Titze de Almeida
Journal:  Molecules       Date:  2018-07-23       Impact factor: 4.411

5.  Reactions of Recombinant Neuronal Nitric Oxide Synthase with Redox Cycling Xenobiotics: A Mechanistic Study.

Authors:  Mindaugas Lesanavičius; Jean-Luc Boucher; Narimantas Čėnas
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.